KR100890875B1 - 가바펜틴 또는 이의 동족체와 α-아미노아미드를 포함하는 약제학적 조성물 및 진통제로서의 이의 용도 - Google Patents

가바펜틴 또는 이의 동족체와 α-아미노아미드를 포함하는 약제학적 조성물 및 진통제로서의 이의 용도 Download PDF

Info

Publication number
KR100890875B1
KR100890875B1 KR1020047003189A KR20047003189A KR100890875B1 KR 100890875 B1 KR100890875 B1 KR 100890875B1 KR 1020047003189 A KR1020047003189 A KR 1020047003189A KR 20047003189 A KR20047003189 A KR 20047003189A KR 100890875 B1 KR100890875 B1 KR 100890875B1
Authority
KR
South Korea
Prior art keywords
gabapentin
gbp
pain
pregabalin
aminoamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020047003189A
Other languages
English (en)
Korean (ko)
Other versions
KR20040034686A (ko
Inventor
살바티파트리차
베네로니오리에따
마로베르토
프리엘로루게로
베나티루카
Original Assignee
뉴론 파마슈티칼즈 에스. 피. 에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 뉴론 파마슈티칼즈 에스. 피. 에이. filed Critical 뉴론 파마슈티칼즈 에스. 피. 에이.
Publication of KR20040034686A publication Critical patent/KR20040034686A/ko
Application granted granted Critical
Publication of KR100890875B1 publication Critical patent/KR100890875B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020047003189A 2001-09-03 2002-08-09 가바펜틴 또는 이의 동족체와 α-아미노아미드를 포함하는 약제학적 조성물 및 진통제로서의 이의 용도 Expired - Lifetime KR100890875B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01121069 2001-09-03
EP01121069.7 2001-09-03
PCT/EP2002/008910 WO2003020273A2 (en) 2001-09-03 2002-08-09 Pharmaceutical composition comprising gabapentin or an analogue thereof and an $g(a)-aminoamide and its analgesic use

Publications (2)

Publication Number Publication Date
KR20040034686A KR20040034686A (ko) 2004-04-28
KR100890875B1 true KR100890875B1 (ko) 2009-03-31

Family

ID=8178510

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047003189A Expired - Lifetime KR100890875B1 (ko) 2001-09-03 2002-08-09 가바펜틴 또는 이의 동족체와 α-아미노아미드를 포함하는 약제학적 조성물 및 진통제로서의 이의 용도

Country Status (20)

Country Link
US (2) US8084447B2 (enExample)
EP (1) EP1423168B1 (enExample)
JP (1) JP4350508B2 (enExample)
KR (1) KR100890875B1 (enExample)
CN (1) CN1274306C (enExample)
AT (1) ATE317280T1 (enExample)
AU (1) AU2002333374B2 (enExample)
BR (1) BRPI0212298B8 (enExample)
CA (1) CA2459470C (enExample)
DE (1) DE60209152T2 (enExample)
DK (1) DK1423168T3 (enExample)
ES (1) ES2253579T3 (enExample)
IL (2) IL160523A0 (enExample)
MX (1) MXPA04002009A (enExample)
NO (1) NO331298B1 (enExample)
NZ (1) NZ531586A (enExample)
PT (1) PT1423168E (enExample)
RU (1) RU2295337C2 (enExample)
SI (1) SI1423168T1 (enExample)
WO (1) WO2003020273A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
EP1169060B1 (en) 1999-04-09 2005-08-31 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8084447B2 (en) 2001-09-03 2011-12-27 Newron Pharmaceuticals S.P.A. Pharmaceutical composition comprising gabapentin or an analogue thereof and an α-aminoamide and its analgesic use
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
JP2006515327A (ja) * 2003-01-30 2006-05-25 ダイノジェン ファーマシューティカルズ， インコーポレイテッド ナトリウムチャネル調節因子を用いた下部尿路障害を処置するための方法
US20040248979A1 (en) * 2003-06-03 2004-12-09 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
SI1658062T1 (sl) * 2003-08-25 2010-05-31 Newron Pharm Spa Alfa aminoamidni derivati uporabni kot protivnetna sredstva
EP1533302A1 (en) * 2003-11-21 2005-05-25 Newron Pharmaceuticals S.p.A. Histidine derivatives
EP1557166A1 (en) * 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
CA2577408C (en) * 2004-09-10 2013-07-09 Elena Barbanti Use of (halobenzyloxy) benzylamino-propanamides for the manufacture of medicaments active as sodium and/or calcium channel selective modulators
US20070043241A1 (en) * 2005-05-10 2007-02-22 Lilach Hedvati Optical resolution of 3-carbamoylmethyl-5-methylhexanoic acid
CN100410242C (zh) * 2005-06-23 2008-08-13 江苏恩华药业股份有限公司 普瑞巴林中间体及其制备方法
BRPI0606118A2 (pt) 2005-09-19 2009-06-02 Teva Pharma uma sìntese assimétrica de (s) - (+) -3- (aminometil) -5- ácido metilhexanóico
EP1798236A1 (en) * 2005-12-13 2007-06-20 EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. Process for the preparation of 3-pyridyl-1-hydroxyethylidene-1,1- biphosphonic acid and hydrated forms thereof
JP5271087B2 (ja) * 2005-12-22 2013-08-21 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー カルシウム及び／又はナトリウムチャネル調節物質としての２−フェニルエチルアミノ誘導体
JP5240476B2 (ja) * 2006-06-19 2013-07-17 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー ２−［４−（３−及び２−フルオロベンジルオキシ）ベンジルアミノ］プロパンアミドの製造方法
CA2689561C (en) 2007-06-15 2015-11-17 Newron Pharmaceuticals S.P.A. Substituted 2- [2- (phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
BRPI0820657A2 (pt) 2007-12-11 2015-06-16 Newron Pharm Spa Processo para a produção de 2-[4-(3- ou 2-fluorobenzilóxi)benzilamino]pro-panamidas com alto grau de pureza
EP2400989B1 (en) 2009-02-24 2016-08-10 Nektar Therapeutics Gabapentin-peg conjugates
HUE030504T2 (en) 2010-04-27 2017-05-29 Newron Pharm Spa Process for the preparation of ralfinamide methanesulfonate salts or their R-enantiomers
EP3846812A2 (en) * 2018-09-04 2021-07-14 Minerva Neurosciences, Inc. Methods of using a phenoxypropylamine compound to treat pain
IT201900006602A1 (it) * 2019-05-07 2020-11-07 Acraf Composizione farmaceutica per il trattamento del dolore neuropatico

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061188A1 (en) 1999-04-09 2000-10-19 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1140748A (en) * 1966-06-23 1969-01-22 Ici Ltd New carboxylic acid derivatives
US3658967A (en) * 1966-06-23 1972-04-25 Ici Ltd Carboxylic acid derivatives for lowering the concentration of triglycerides in the blood
CH480308A (de) * 1966-08-11 1969-10-31 Ciba Geigy Verfahren zur Herstellung von Thiosemicarbazid-Verbindungen
US4049663A (en) * 1972-06-06 1977-09-20 Allen & Hanburys Limited Ethylene diamine derivatives
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
US4311853A (en) * 1979-02-06 1982-01-19 The Radiochemical Centre Limited Selenium derivatives of thyroxine and tri-iodothyronine
DE3050800C2 (enExample) 1979-03-22 1989-06-22 Continental Pharma Inc., Bruessel/Bruxelles, Be
US4267354A (en) * 1979-04-25 1981-05-12 E. R. Squibb & Sons, Inc. Substituted amides having antiinflammatory activity and intermediates
ZA803250B (en) * 1979-06-01 1982-01-27 Wellcome Found Substituded aromatic compounds
ZA805476B (en) 1979-09-26 1981-11-25 Robins Co Inc A H 2-amino-3-benzoyl-phenylacetamides and cyclic homologues
FR2480747A1 (fr) * 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
DE3483308D1 (de) * 1983-11-21 1990-10-31 Fujisawa Pharmaceutical Co Semicarbazid-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
US4631287A (en) * 1985-04-16 1986-12-23 Usv Pharmaceutical Corp. Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4839369A (en) 1985-04-16 1989-06-13 Rorer Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4725619A (en) 1985-04-16 1988-02-16 Usv Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
GB8714901D0 (en) * 1986-07-23 1987-07-29 Ici Plc Amide derivatives
GB2216515A (en) * 1988-03-04 1989-10-11 Nippon Shinyaku Co Ltd Acylphenol derivatives
US4894476A (en) * 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
FR2639225B1 (fr) * 1988-11-21 1993-05-21 Centre Nat Rech Scient Compositions pharmaceutiques pour la neuroprotection contenant des arylcyclohexylamines
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
DE3928488A1 (de) 1989-08-29 1991-03-07 Standard Elektrik Lorenz Ag Interferometrisches messsystem
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
DE69224861T2 (de) 1991-07-30 1998-08-06 Korea Res Inst Chem Tech Neue Phenylacetamidderivate und Verfahren zu ihrer Herstellung
GB9203483D0 (en) * 1992-02-19 1992-04-08 Wellcome Found Anti-inflammatory compounds
US5330515A (en) * 1992-06-17 1994-07-19 Cyberonics, Inc. Treatment of pain by vagal afferent stimulation
US5256669A (en) * 1992-08-07 1993-10-26 Aminotek Sciences, Inc. Methods and compositions for treating acute or chronic pain and drug addiction
US5498610A (en) * 1992-11-06 1996-03-12 Pfizer Inc. Neuroprotective indolone and related derivatives
GB9306899D0 (en) 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylalkylaminobenzyl) aminopropionamide derivatives and process for their preparation
GB9306886D0 (en) 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
US5475007A (en) * 1993-05-28 1995-12-12 The Regents Of The University Of California 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oximes and the use thereof
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5482964A (en) * 1994-10-11 1996-01-09 Warner-Lambert Company Substituted phenoxyhydroxypropyl amines as central nervous system agents
US5541204A (en) * 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
GB9426102D0 (en) * 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
KR0147963B1 (ko) 1995-01-10 1998-08-17 강박광 엔-아릴알킬페닐아세트아미드 유도체와 그의 제조방법
US5849737A (en) * 1995-04-14 1998-12-15 The Regents Of The University Of California Compositions and methods for treating pain
US5741818A (en) * 1995-06-07 1998-04-21 University Of Saskatchewan Semicarbazones having CNS activity and pharmaceutical preparations containing same
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
US5795864A (en) * 1995-06-27 1998-08-18 Neurex Corporation Stable omega conopetide formulations
GB9515412D0 (en) * 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9515411D0 (en) 1995-07-27 1995-09-27 Pharmacia Spa N-(4-substituted-benzyl)-2-aminolactam derivatives
US5688830A (en) * 1996-01-25 1997-11-18 Syntex (U.S.A.) Inc. Treatment of neuropathic pain
US6372792B1 (en) * 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
NZ332762A (en) 1996-07-24 2000-09-29 Warner Lambert Co Isobutylgaba and its derivatives for the treatment of pain
ATE293458T1 (de) * 1996-08-23 2005-05-15 Algos Pharm Corp Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
US6172085B1 (en) 1996-08-29 2001-01-09 Takeda Chemical Industries, Ltd. Cyclic ether compounds as sodium channel modulators
US6290986B1 (en) * 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
CA2270531C (en) 1996-11-05 2011-08-30 Head Explorer Aps A method for treating tension-type headache
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US6207685B1 (en) * 1996-12-06 2001-03-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Therapeutic application of a thienycyclohexylamine derivative
FR2756738B1 (fr) 1996-12-06 1999-02-12 Sod Conseils Rech Applic Nouvelle application therapeutique d'un derive de la thienylcyclohexylamine
IL119890A (en) 1996-12-24 2002-03-10 Teva Pharma Gabapentin form iii and preparation of gabapentin form ii
GB9706730D0 (en) 1997-04-03 1997-05-21 Pharmacia & Upjohn Spa 2-[(3-substituted)-5-Isoxazolymethylaminojalkanamid derivatives
NZ500590A (en) 1997-04-22 2001-11-30 Cocensys Inc Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof
AU8668598A (en) * 1997-08-20 1999-03-08 University Of Oklahoma, The Gaba analogs to prevent and treat gastrointestinal damage
JP3782935B2 (ja) * 1997-09-08 2006-06-07 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 抗癲癇化合物を含有する鎮痛剤組成物およびその使用方法
EP1032377B1 (en) 1997-11-21 2010-11-17 Purdue Neuroscience Company Substituted 2-aminoacetamides and the use thereof
GB9727523D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
GB9727521D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Substituted 2-benzylamino-2-phenyl-acetamide compounds
WO1999037296A1 (en) 1998-01-23 1999-07-29 Warner-Lambert Company Gabapentin and its derivatives for the treatment of muscular and skeletal pain
US5905069A (en) * 1998-01-26 1999-05-18 The General Hospital Corporation Methods of decreasing or preventing pain using spicamycin or derivatives thereof
AU754681B2 (en) 1998-02-04 2002-11-21 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
GB9804885D0 (en) 1998-03-06 1998-04-29 Merck Sharp & Dohme Therapeutic combination
ES2137137B1 (es) 1998-05-25 2000-08-16 Medichem Sa Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica.
BR9911917A (pt) * 1998-07-09 2001-03-27 Warner Lambert Co Composições compreendendo análogos de gaba e cafeìna
ES2230863T3 (es) 1998-07-09 2005-05-01 Warner-Lambert Company Llc Composicion farmaceutica que contiene analogos de gaba y un agente antivirico para el tratamiento del herpres zoster.
US6281211B1 (en) * 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
BR0008847A (pt) * 1999-03-10 2001-12-26 Warner Lambert Co Composições analgésicas que compreendemcompostos antiepilépticos, e métodos de uso dasmesmas
KR20020015308A (ko) 1999-03-26 2002-02-27 추후보정 아릴 치환된 피라졸, 이미다졸, 옥사졸, 티아졸 및 피롤,및 이의 용도
WO2001007037A1 (en) * 1999-07-22 2001-02-01 University Of Rochester Method of treating symptoms of hormonal variation, including hot flashes
JP2003506388A (ja) * 1999-08-04 2003-02-18 アイカゲン インコーポレイテッド 疼痛および不安症を処置または予防するための方法
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
GB9930079D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
WO2001098779A2 (en) * 2000-06-19 2001-12-27 Merck Frosst Canada & Co. Methods of identifying gabab receptor subtype-specific agonists
EP1229332A3 (en) * 2001-02-02 2004-07-28 Warner-Lambert Company In vitro assay for testing gabapentinoid activity
US8084447B2 (en) 2001-09-03 2011-12-27 Newron Pharmaceuticals S.P.A. Pharmaceutical composition comprising gabapentin or an analogue thereof and an α-aminoamide and its analgesic use
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
EP1588704A1 (en) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
CA2577408C (en) * 2004-09-10 2013-07-09 Elena Barbanti Use of (halobenzyloxy) benzylamino-propanamides for the manufacture of medicaments active as sodium and/or calcium channel selective modulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061188A1 (en) 1999-04-09 2000-10-19 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof

Also Published As

Publication number Publication date
CA2459470A1 (en) 2003-03-13
US20120142777A1 (en) 2012-06-07
NO331298B1 (no) 2011-11-21
WO2003020273A2 (en) 2003-03-13
IL160523A (en) 2009-02-11
JP4350508B2 (ja) 2009-10-21
US8084447B2 (en) 2011-12-27
US8710040B2 (en) 2014-04-29
DK1423168T3 (da) 2006-05-15
NZ531586A (en) 2005-09-30
EP1423168A2 (en) 2004-06-02
US20040248978A1 (en) 2004-12-09
DE60209152D1 (de) 2006-04-20
BRPI0212298B1 (pt) 2015-11-03
IL160523A0 (en) 2004-07-25
NO20040907L (no) 2004-05-14
HK1070305A1 (en) 2005-06-17
CN1274306C (zh) 2006-09-13
DE60209152T2 (de) 2006-08-03
PT1423168E (pt) 2006-05-31
RU2004110041A (ru) 2005-03-10
ES2253579T3 (es) 2006-06-01
WO2003020273A3 (en) 2003-09-04
AU2002333374A2 (en) 2003-03-18
MXPA04002009A (es) 2004-07-08
CA2459470C (en) 2010-10-12
EP1423168B1 (en) 2006-02-08
RU2295337C2 (ru) 2007-03-20
SI1423168T1 (sl) 2006-06-30
BRPI0212298B8 (pt) 2021-05-25
CN1556720A (zh) 2004-12-22
JP2005504782A (ja) 2005-02-17
BR0212298A (pt) 2004-09-14
AU2002333374B2 (en) 2007-03-22
ATE317280T1 (de) 2006-02-15
KR20040034686A (ko) 2004-04-28

Similar Documents

Publication Publication Date Title
KR100890875B1 (ko) 가바펜틴 또는 이의 동족체와 α-아미노아미드를 포함하는 약제학적 조성물 및 진통제로서의 이의 용도
EP1082292B1 (en) Control of pain with endogenous cannabinoids
AU2002333374A1 (en) Pharmaceutical composition comprising gabapentin or an analogue thereof and an (alpha)- aminoamide and its analgesic use
PL213323B1 (pl) Kompozycja farmaceutyczna i jej zastosowanie
JP6336592B2 (ja) ヒスタミンｈ４受容体を介してもたらされた掻痒状態を治療するための医薬組成物
EP2148669A1 (de) Tapentadol zur schmerzbehandlung bei arthrose
JP4933265B2 (ja) フルピルチン及びトラマドールの組み合わせ
US20090042987A1 (en) Treatment of neuropathic pain
KR20070121032A (ko) 네포팜 및 그 유사체의 치료학적 용도
AU763273B2 (en) Analgesic regimen
EP1645270B1 (en) Control of pain with ANANDAMIDE
Freeman Newer agents for the treatment of painful diabetic peripheral neuropathy
MX2008014287A (es) Mirtazapina para el tratamiento del dolor neuropatico.
JP2020525548A (ja) 炎症反応を伴う疼痛状態における鎮痛のための末梢限局的二重作用性κおよびδオピオイドアゴニスト
Lascelles Non-NSAID drug therapy for canine DJD-associated pain.
HK1096884A (en) Combination of flupirtine and tramadol

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20040303

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20070704

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20081125

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20090130

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20090323

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20090324

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20120309

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20130311

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20130311

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20140311

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20140311

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20150309

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20150309

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20160309

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20160309

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20180308

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20180308

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20190313

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20190313

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20200312

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20200312

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20210316

Start annual number: 13

End annual number: 13

PR1001 Payment of annual fee

Payment date: 20220308

Start annual number: 14

End annual number: 14

PC1801 Expiration of term

Termination date: 20230209

Termination category: Expiration of duration